Le Lézard
Classified in: Health

Kangen Pharmaceuticals Co., Ltd. Announces Acquisition Of KC Specialty Therapeutics.


TOKYO and KANSAS CITY, Kan., Dec. 13, 2017 /PRNewswire/ -- Kangen Pharmaceuticals ("Kangen") and KC Specialty Therapeutics ("KCST") today announced that Kangen has reached an agreement with KCST and agreed to acquire the assets of KCST. Kangen intends to retain operations in Kansas City, Kansas, USA, with expansions in Japan and the US.

Kangen Pharmaceuticals Co., Ltd.

"This is a significant milestone for both Kangen and KCST. This acquisition provides Kangen with a unique opportunity for growth in two major markets ? the US and Japan," said Mr. Norihiro Hirota, Chairperson and President of Kangen.

KCST has an existing portfolio of products focused on niche indications, and orphan drug designations.  This acquisition also creates for Kangen an expanded network of affiliates and alliances in Asia and Europe, where Kangen will further expand strategic business alliances and portfolio of branded pharmaceuticals.

Diana Wood, CEO of KCST added, "This acquisition brings together complementary strengths of Kangen and KCST and also enhances our strategic position and value with our partners in Japan." Diana Wood will take on the additional role of the President of Kangen, while Mr. Hirota will retain the chairperson position.

About Kangen
Kangen Pharmaceuticals Co., Ltd. was founded in 2005 by Mr. Hirota.  Kangen, formerly known as Stason Pharma Japan, has been instrumental in establishing strategic relationships between KCST and its partners in Japan, now with several ongoing projects in various stages of the FDA review process.­ For more information, please visit: www.Kangenpharma.com

About KC Specialty
KC Specialty Therapeutics, LLC is a US-based pharmaceutical company focused on the development of quality therapeutics for niche markets, and unmet medical need such as for orphan indications. KC Specialty is headquartered in Kansas City, KS and was founded in 2012 as a subsidiary of Stason Pharmaceuticals, which entered the US market in 1994. Under the management of CEO, Diana Wood, KC Specialty has extensive expertise in brand drug development, and navigation of complex regulatory pathways, which will compliment Kangen's strategic alliances, worldwide. For more information, please visit: www.KCSpecialty.com

 

SOURCE Kangen Pharmaceuticals Co., Ltd.


These press releases may also interest you

at 14:15
Project Lyme Harnesses the Power of Public Service Announcements to Inform Parents Their Child's Complex Illness Could Be Lyme
The CDC now estimates nearly half a million people will contract Lyme disease in the United States each year. However, most people do not realize how Lyme disease can cause diverse, devastating symptoms in some patients. The range of symptoms is...

at 14:15
Genesis Unveils Emerging Technology, HOCl Atomizing, for 'Air Quality Awareness Week'
Frederick, MD-based Genesis + HOCL introduces two HOCl atomizing machines for Air Quality Awareness Week. Genesis is the sole U.S. distributor of this technology, previously only available in Japan and South Korea, bringing the Genesis 2.6 and UX4 to...

at 14:09
The Independence Fund hosts "Beyond the Call" Luncheon Fundraiser to Support Caregivers of Our Nation's Heroes
The Independence Fund proudly presents "Beyond the Call" luncheon, a fundraising event dedicated to honoring and supporting the Caregivers of our nation's wounded Veterans. Join the event on May 16, 2024, at 11:00 AM at the Duke Mansion in Charlotte,...

at 14:05
Avicenna Introduces Machine Learning-Enhanced Medicinal Chemistry Platform to Accelerate the Last Mile of Small Molecule Drug Discovery
Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery. The company has raised $14.5 million in funding to date, with DCVC Bio...

at 14:00
Rendina Healthcare Real Estate Announces the Grand Opening of Inspira Health Center Deptford
Rendina Healthcare Real Estate is proud to announce the official opening of Inspira Health Center Deptford, a state-of-the-art outpatient health center in Deptford, NJ. This significant development is the result of a fruitful partnership with Inspira...

at 14:00
Strengthening CAR-T Therapy to Work Against Solid Tumors
Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors?an advance that could transform...

More news about Health...


News published on and distributed by: